The USFDA has issued a warning letter to Vista Pharmaceutical Ltd for ‘violation’ of Current Good Manufacturing Practices at its plant in Gopalapally, Nalgonda district. According to the letter issued about a week ago, it found ‘significant’ violations in the inspection it conducted last year. The facility makes finished dosages/pharmaceuticals. The company’s scrip fell 4.93 per cent on the BSE on Wednesday to end at ₹32.75.